Drug Landscape ›
Echinacea Extract ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 40
Most-reported reactions
Back Pain — 5 reports (12.5%) Diarrhoea — 5 reports (12.5%) Asthenia — 4 reports (10%) Chills — 4 reports (10%) Drug Interaction — 4 reports (10%) Fatigue — 4 reports (10%) Myalgia — 4 reports (10%) Vomiting — 4 reports (10%) Arthralgia — 3 reports (7.5%) Condition Aggravated — 3 reports (7.5%)
Source database →
Echinacea Extract in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Echinacea Extract approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Echinacea Extract in United States?
Al-Azhar University is the originator. The local marketing authorisation holder may differ — check the official source linked above.